All News

Top news of the day from across the health care landscape.

Approximately 2 out of 6 study participants tested positive after vaping cannabis that contained 0.39% THC using urine testing methods.

With this approval, enzalutamide is the first and only oral treatment approved by the FDA in 3 distinct types of advanced prostate cancer.

The CDC reported progress with the current status of the 3 strategies within the national initiative, Ending the HIV Epidemic: A Plan for America.

The immunogenicity and safety of hepatitis B surface antigen (HBsAg)/CpG 1018 was assessed in patients with diabetes aged 60 to 70 years.

A retrospective cohort study was the second largest evaluation to date of sodium polystyrene sulphonate use and safety in patients with chronic kidney disease.

What is causing a patient’s memory loss?

Icosapent ethyl is the first FDA-approved prescription form of fish oil to reduce cardiovascular risk among patients with triglyceride levels as an add-on to maximally tolerated statin therapy.

The supplemental new drug application approval expands the patient population who stand to benefit from riluzole to include patients with ALS for whom swallowing is difficult and requires the use of percutaneous endoscopic gastrostomy feeding tube.

Top news of the day from across the health care landscape.

Results of the DAPA-HF trial demonstrate the efficacy and safety of dapagliflozin in patients with heart failure.

In this study, researchers wanted to evaluate the frequency of reduced immunoglobulin concentrations and its association with immunotherapy and disease course in 2 independent cohorts with multiple sclerosis.

A study using genomics and proteomics identified new subtypes of clear cell renal cell carcinoma based on tumor microenvironment signatures.

The Trend Report is a synthesis of multiple research projects exploring risk factors that influence medication adherence, along with background and implications.

A report suggests that addressing financial barriers to antiretroviral therapy adherence may improve levels of viral suppression.

More men than women initiate kidney replacement therapy despite a higher prevalence of chronic kidney disease seen in women.

The FDA has granted accelerated approval to golodirsen injection (Vyondys 53, Sarepta Therapeutics) to treat patients with Duchenne muscular dystrophy (DMD) who have confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping.

Top news of the week from Specialty Pharmacy Times.

Top news of the day from across the health care landscape.